Five Studies Point To Effectiveness Of Artelo Biosciences’ CBD Drug Candidate For Cancer Pain – FDA IND Application The Next Step - Artelo Biosciences (NASDAQ:ARTL)

Greg Gorgas, President & CEO of Artelo Biosciences ARTL, was recently a guest on Benzinga’s All-Access.

Artelo is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system.

Artelo has a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy and inflammation.

Mr. Gorgas addressed the positive results from recent studies surrounding one of its drug candidates designed to alleviate pain in cancer patients. The company is looking ahead to the next step toward FDA approval.

Learn more here:

Featured photo by Sangga Rima Roman Selia on Unsplash

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Five Studies Point To Effectiveness Of Artelo Biosciences' CBD Drug Candidate For Cancer Pain – FDA IND Application The Next Step